Phase I trial characteristics include which combination of primary interest, population, design, and enrollment size?

Study for the Clinical Research and Ethical Considerations Test. Enhance your understanding with multiple choice questions covering essential ethical guidelines and research methodologies. Prepare effectively for your test!

Phase I studies are focused on safety and dose finding. They typically explore how the drug behaves in the body and assess tolerability, aiming to identify a safe dosing range. Because the goal is early safety signals, these trials usually involve a small number of participants, often healthy volunteers to minimize confounding factors, though some drugs tested in patients may also use affected populations when appropriate. The design is commonly dose-escalation, unblinded, and uncontrolled, which allows investigators to quickly determine how increasing doses affect safety and to establish the starting point for later trials. Enrollments are modest, usually around dozens to about fifty participants, and the duration is relatively short—often around a month to less than a year.

The option describing safety/tolerability as the primary interest, healthy volunteers as the population, a dose-escalation, unblinded, uncontrolled design, a duration near one month to under a year, and enrollment about fifty aligns with this Phase I pattern.

Other options emphasize efficacy, longer-term safety, general population or observational study styles, or designs like randomized, blinded, cross-over, or studies aimed at regulatory approval in pediatrics. Those characteristics fit later-phase trials or different study types rather than Phase I.